Printer Friendly
The Free Library
14,506,104 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Guidant Announces European Approval of Next Generation Cardiac Resynchronization Therapy Defibrillator.


INDIANAPOLIS, Ind. & ST. PAUL, Minn. -- Guidant Corporation (NYSE NYSE

See: New York Stock Exchange
:GDT GDT Global Descriptor Table
GDT Geographic Data Technology Inc.
GDT Gas Discharge Tube (energy, electrotechinical and electronics)
GDT Getting Things Done
GDT Geometric Dimensioning & Tolerancing
GDT Ground Data Terminal
)

Innovative System Combines Treatments for Heart Failure, Atrial Arrhythmias and Sudden Cardiac Death Sudden Cardiac Death Definition

Sudden cardiac death (SCD) is an unexpected death due to heart problems, which occurs within one hour from the start of any cardiac-related symptoms. SCD is sometimes called cardiac arrest.
 

Guidant Corporation (NYSE:GDT) today announced Conformite Europeenne (CE) Mark approval and first implant of its CONTAK RENEWAL(R) 4 AVT AVT

avian arginine vasotocin. See vasotocin.
 cardiac resynchronization therapy defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a . The system is designed to treat heart failure patients who are at risk for sudden cardiac death and also suffer from atrial arrhythmias. Atrial arrhythmias affect approximately half of the 6.5 million Europeans and 5 million Americans who suffer from heart failure. Guidant will launch the CONTAK RENEWAL 4 AVT system in Europe later this quarter.

"Not only is atrial fibrillation atrial fibrillation

Irregular rhythm (arrhythmia) of contraction of the atria (upper heart chambers). The most common major arrhythmia, it may result as a consequence of increased fibrous tissue in the aging heart, of heart disease, or in association with severe infection.
 one of the more important co-morbidities in heart failure, it is also difficult to treat," said Johannes Sperzel, M.D., at Kerckhoff-Klinik, Bad Nauheim, Germany, where the first implant was performed earlier this month. "The availability of a cardiac resynchronization therapy defibrillator that can also diagnose and treat an atrial arrhythmia has enormous potential for millions of heart failure patients worldwide because it enables physicians to treat both the upper and lower chambers of the heart."

"The RENEWAL 4 AVT is a tangible example of our capability to deliver meaningful product innovation," said Fred McCoy, president, Cardiac Rhythm Management Cardiac rhythm management is a field of treatment in cardiology. The purpose is managing cardiac rhythm disorders. Usually it involves artificial pacemakers and/or implantable cardioverter-defibrillator therapy as well as antiarrhythmia drugs. , Guidant Corporation. "We are pleased to provide this new treatment option to our physician customers for the patients they serve."

The CONTAK RENEWAL 4 AVT system is designed to determine the origin of an irregular heartbeat and provide the appropriate therapy. Once the origin and severity of the arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of  is determined, the device provides either pacing therapy or delivers an appropriate shock to return the heart to a normal rhythm. The RENEWAL 4 AVT system's diagnostic tools also assist physicians in accurately diagnosing a patient's condition, documenting symptoms, gaining clear insight into disease progression and monitoring the effectiveness of the therapy.

About Atrial Arrhythmias

Atrial arrhythmias are irregular beats that begin in the heart's upper chamber. Normally, the electrical signal that tells your heart to beat comes from the sinoatrial node, or SA node, in the right atrium. But during atrial fibrillation, signals start irregularly from several areas in the atria Atria
The heart has four chambers. The right and left atria are at the top of the heart and receive returning blood from the veins. The right and left ventricles are at the bottom of the heart and act as the body's main pumps.
. These disorganized dis·or·gan·ize  
tr.v. dis·or·gan·ized, dis·or·gan·iz·ing, dis·or·gan·iz·es
To destroy the organization, systematic arrangement, or unity of.
 electrical signals cause the atria to quiver rapidly and irregularly, instead of beating in a regular rhythm. Atrial fibrillation keeps the heart's upper and lower chambers from working together properly. This can decrease the heart's pumping efficiency by as much as 20 to 30 percent. Additionally, people with untreated atrial fibrillation may be at significantly greater risk for stroke than people with normal heart rhythms. Because blood does not flow through the atria smoothly, blood clots may form in the heart. If a blood clot is dislodged from the heart, it can travel to the brain and result in stroke.

About Guidant

Guidant Corporation is a world leader in the treatment of cardiac and vascular disease. The company pioneers lifesaving technology, giving an opportunity for better life today to millions of cardiac and vascular patients worldwide. Driven by a strong entrepreneurial culture of 12,000 employees, Guidant develops, manufactures and markets a broad array of products and services that enable less invasive care for some of life's most threatening medical conditions.

NOTE TO MEDIA: For more information about heart failure and sudden cardiac death, please visit the company's newsroom at www.guidant.com/newsroom.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 21, 2004
Words:555
Previous Article:General Physics Corporation Becomes Sponsor of TrainingOutsourcing.com.
Next Article:Turbolinux First to Bundle Commercial DVD Player for Linux.
Topics:



Related Articles
Guidant Announces U.S. Approval of Next Generation Heart Failure Therapy System; Cardiac Resynchronization Therapy-Defibrillator Represents the...
Guidant Announces European Approval and First Implant of Next Generation Heart Failure Therapy System.
Guidant Announces Clinical Trial for Cardiac Resynchronization Therapy Defibrillator that Combines Treatment for both Heart Failure and Atrial...
Guidant Announces U.S. Launch of Cardiac Resynchronization Therapy Pacemaker; Guidant Receives FDA Approval Based on COMPANION Clinical Trial Data.
Results of Guidant's Landmark Heart Failure Trial Published in New England Journal of Medicine.
U.S. Food and Drug Administration Panel to Review Results of Guidant's Landmark Heart Failure Trial.
Guidant's Heart Failure Therapy Unanimously Recommended for a Broader Patient Population.
Guidant Receives Exclusive Expanded Indication for Heart Failure Treatment; Thousands of Additional Patients Now Eligible to Receive Cardiac...
Guidant Receives FDA Approval to Re-enter Heart Failure Market; Company Expects to Resume Implants and Distribution by Mid-week.
Guidant to Launch New Wireless Heart Failure Communication Technology System in U.S.; Guidant Announces Full Availability of Cardiac Rhythm...

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles